BiVictriX Therapeutics Plc (BVX.L) LSE
10.00
+1.5(+17.65%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
10.00
+1.5(+17.65%)
Currency In GBp
Address
Bio Hub
Macclesfield, SK10 4TG
United Kingdom of Great Britain and Northern Ireland (the)
Phone
N/A
Website
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
August 11, 2021
| Name | Title | Pay | Year Born |
| Tiffany Jane Thorn | Chief Executive Officer & Executive Director | 226,375 | 1987 |
| Alison Halsall Lindsay | Secretary | 0 | N/A |
| Adrian Howd | Chief Business Officer & Chief Financial Officer | 0 | 1971 |
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.